Ascentage (AAPG) Total Debt to Capital

Ascentage Pharma Group focuses on developing cutting-edge anti-aging and anti-tumor agents, targeting the global targeted therapy sector. The Chinese developer is patenting unique inhibitors, the costs of which are regulated by government reimbursement programs. This price chart demonstrates a total debt-to-equity ratio of 3.67. Investors highly value the brand's scientific foundation, viewing the company as a promising leader in its field.

The leverage ratio measures the proportion of total liabilities relative to equity, determining the degree of financial autonomy and the business's resilience to liquidity shortages. Analyzing the debt-to-equity ratio allows for an assessment of the bankruptcy risk of Ascentage Pharma Group (AAPG), whose capital-intensive biotechnological ecosystem requires significant investments in the development of targeted molecules to combat oncology.